Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN D PASCOE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1467460774
CMS profile
1145429
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$32.40

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $32.40 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $32.40 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN D PASCOE

NPI 1467460774 · CMS profile ID 1145429

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467460774?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN D PASCOE, NPI 1467460774, CMS profile ID 1145429. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467460774?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOHN D PASCOE, NPI 1467460774, CMS profile ID 1145429. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467460774?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOHN D PASCOE, NPI 1467460774, CMS profile ID 1145429, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1467460774?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $32.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $32.4004/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944051559 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $32.40 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $6,118.99 1
PY2023 Principal investigator $1,775.00 2
PY2022 Principal investigator $27,475.73 4
PY2021 Principal investigator $218,154.04 51
PY2020 Recipient $1,354.27 7
PY2020 Principal investigator $1,170,513.03 182
PY2019 Principal investigator $891,784.39 70

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

189 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $9,028.75 12/31/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721316259
Principal investigator 1 Allergan, Inc. $19,599.93 12/31/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721316401
Principal investigator 1 Corcept Therapeutics $800.00 12/30/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-877 No dispute reported 06/30/2026 745568823
Principal investigator 1 Corcept Therapeutics $9,700.00 12/30/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-877 No dispute reported 06/30/2026 745568825
Principal investigator 1 Corcept Therapeutics $3,000.00 12/30/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-877 No dispute reported 06/30/2026 745568827
Principal investigator 1 Corcept Therapeutics $3,000.00 12/30/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-877 No dispute reported 06/30/2026 745568829
Principal investigator 1 Corcept Therapeutics $5,000.00 12/23/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-877 No dispute reported 06/30/2026 745568819
Principal investigator 1 Corcept Therapeutics $1,000.00 12/23/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-877 No dispute reported 06/30/2026 745568821
Principal investigator 1 Corcept Therapeutics $3,000.00 12/23/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-877 No dispute reported 06/30/2026 745568831
Principal investigator 1 Sage Therapeutics, Inc. $60.00 12/17/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749046271
Principal investigator 1 Allergan, Inc. $11,337.30 12/15/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721312657
Principal investigator 1 Allergan, Inc. $26,693.10 12/15/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721312741
Principal investigator 1 Allergan, Inc. $75.00 12/04/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721310897
Principal investigator 1 Allergan, Inc. $200.00 12/04/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721310899
Principal investigator 1 Allergan, Inc. $16,800.00 12/04/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721310901
Principal investigator 1 Allergan, Inc. $325.00 12/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721310793
Principal investigator 1 Allergan, Inc. $325.00 12/01/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721310155
Principal investigator 1 Allergan, Inc. $12,600.00 12/01/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721310159
Principal investigator 1 Allergan, Inc. $19,600.00 12/01/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721310161
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $7,472.00 11/26/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER No dispute reported 06/30/2026 748806037
Principal investigator 1 Allergan, Inc. $325.00 11/17/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721308501
Principal investigator 1 Allergan, Inc. $20,767.00 11/16/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721308031
Principal investigator 1 Allergan, Inc. $17,195.00 11/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721307761
Principal investigator 1 Allergan, Inc. $19,600.00 11/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721307783
Principal investigator 1 Allergan, Inc. $2,800.00 11/10/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721307505
Principal investigator 1 Allergan, Inc. $19,600.00 11/06/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721307043
Principal investigator 1 Allergan, Inc. $20,000.00 11/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721306357
Principal investigator 1 Allergan, Inc. $200.00 11/02/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721306051
Principal investigator 1 Allergan, Inc. $150.00 11/01/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721305917
Principal investigator 1 Allergan, Inc. $325.00 11/01/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721305919
Principal investigator 1 Allergan, Inc. $327.00 10/29/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721305531
Principal investigator 1 Allergan, Inc. $325.00 10/27/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721305385
Principal investigator 1 Allergan, Inc. $300.00 10/22/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721305103
Principal investigator 1 Allergan, Inc. $9,800.00 10/22/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721305105
Principal investigator 1 Allergan, Inc. $325.00 10/21/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721304569
Principal investigator 1 Allergan, Inc. $650.00 10/21/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721304571
Principal investigator 1 Allergan, Inc. $325.00 10/21/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721304577
Principal investigator 1 Allergan, Inc. $325.00 10/21/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721304579
Principal investigator 1 Allergan, Inc. $650.00 10/21/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721304581
Principal investigator 1 Allergan, Inc. $325.00 10/19/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721303647
Principal investigator 1 Allergan, Inc. $325.00 10/19/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721303649
Principal investigator 1 Allergan, Inc. $2,800.00 10/19/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721303655
Principal investigator 1 Allergan, Inc. $22,062.80 10/14/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721302469
Principal investigator 1 Allergan, Inc. $304.00 10/01/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721301173
Principal investigator 1 Allergan, Inc. $400.00 09/25/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721300583
Principal investigator 1 Corcept Therapeutics $1,399.50 09/25/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568781
Principal investigator 1 Sage Therapeutics, Inc. $6,275.00 09/17/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749044717
Principal investigator 1 Sage Therapeutics, Inc. $5,000.00 09/17/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749044719
Principal investigator 1 Sage Therapeutics, Inc. $1,000.00 09/17/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749044721
Principal investigator 1 Sage Therapeutics, Inc. $2,000.00 09/17/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749044723
Principal investigator 1 Allergan, Inc. $30,126.40 09/15/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721297395
Principal investigator 1 Allergan, Inc. $7,602.85 09/15/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721297467
Principal investigator 1 Allergan, Inc. $325.00 09/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721295445
Principal investigator 1 Allergan, Inc. $325.00 09/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721295455
Principal investigator 1 Allergan, Inc. $325.00 08/19/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721291265
Principal investigator 1 Allergan, Inc. $7,681.70 08/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721289993
Principal investigator 1 Allergan, Inc. $23,690.15 08/12/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721289727
Principal investigator 1 Allergan, Inc. $371.00 08/11/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721289135
Principal investigator 1 Corcept Therapeutics $4,338.90 08/03/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568779
Principal investigator 1 Allergan, Inc. $371.00 07/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 721287441
Principal investigator 1 Corcept Therapeutics $120.90 07/28/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568777
Principal investigator 1 Allergan, Inc. $44,630.05 07/14/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721283873
Principal investigator 1 Allergan, Inc. $15,564.80 07/14/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721283939
Principal investigator 1 Allergan, Inc. $4,200.00 07/07/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721283003
Principal investigator 1 Allergan, Inc. $325.00 07/06/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721282697
Principal investigator 1 Allergan, Inc. $400.00 07/06/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721282699
Principal investigator 1 Corcept Therapeutics $7,506.00 07/06/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568775
Principal investigator 1 Allergan, Inc. $325.00 06/26/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721282111
Principal investigator 1 Allergan, Inc. $19,600.00 06/22/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721281111
Principal investigator 1 Allergan, Inc. $45,703.55 06/16/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721280151
Principal investigator 1 Allergan, Inc. $75.00 06/15/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721279523
Principal investigator 1 Allergan, Inc. $325.00 06/15/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721279525
Principal investigator 1 Allergan, Inc. $400.00 06/15/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721279591
Principal investigator 1 Allergan, Inc. $18,716.90 06/15/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721279593
Principal investigator 1 Allergan, Inc. $19,600.00 06/12/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721279359
Principal investigator 1 Allergan, Inc. $19,600.00 06/12/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721279361
Principal investigator 1 Allergan, Inc. $650.00 06/09/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721279023
Principal investigator 1 Allergan, Inc. $375.00 06/05/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721278857
Principal investigator 1 Allergan, Inc. $400.00 06/05/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721278859
Principal investigator 1 Allergan, Inc. $19,600.00 06/05/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721278861
Principal investigator 1 Allergan, Inc. $19,600.00 06/05/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721278863
Principal investigator 1 Allergan, Inc. $19,600.00 06/05/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721278865
Principal investigator 1 Allergan, Inc. $700.00 06/04/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 721278729
Principal investigator 1 Allergan, Inc. $1,300.00 06/04/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721278793
Principal investigator 1 Allergan, Inc. $650.00 06/04/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721278805
Principal investigator 1 Allergan, Inc. $8,400.00 06/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721278567
Principal investigator 1 Allergan, Inc. $400.00 06/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721278569
Principal investigator 1 Allergan, Inc. $400.00 06/01/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721278227
Principal investigator 1 Allergan, Inc. $2,800.00 06/01/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721278229
Principal investigator 1 Allergan, Inc. $75.00 06/01/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721278239
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $25,353.00 05/28/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER No dispute reported 06/30/2026 748804995
Principal investigator 1 Allergan, Inc. $975.00 05/22/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721276693
Principal investigator 1 Allergan, Inc. $19,600.00 05/22/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721276695
Principal investigator 1 Allergan, Inc. $327.00 05/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 721276215
Principal investigator 1 Allergan, Inc. $27,242.20 05/21/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721276565
Principal investigator 1 Allergan, Inc. $300.00 05/19/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721275621
Principal investigator 1 Corcept Therapeutics $9,675.00 05/18/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568759
Principal investigator 1 Allergan, Inc. $11,724.90 05/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721274729
Principal investigator 1 Allergan, Inc. $325.00 05/11/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721274061
Principal investigator 1 Sage Therapeutics, Inc. $2,280.00 04/29/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH A FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749042787
Principal investigator 1 Allergan, Inc. $75.00 04/27/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721272879
Principal investigator 1 Allergan, Inc. $325.00 04/27/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721272881
Principal investigator 1 Allergan, Inc. $325.00 04/27/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721272883
Principal investigator 1 Allergan, Inc. $19,600.00 04/27/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721272885
Principal investigator 1 Allergan, Inc. $371.00 04/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721272499
Principal investigator 1 Allergan, Inc. $325.00 04/23/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721272661
Principal investigator 1 Allergan, Inc. $400.00 04/21/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721271753
Principal investigator 1 Allergan, Inc. $24,784.55 04/17/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721271069
Principal investigator 1 Allergan, Inc. $13,631.55 04/16/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721270789
Principal investigator 1 Corcept Therapeutics $8,094.60 04/10/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568757
Principal investigator 1 Allergan, Inc. $400.00 04/09/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721269391
Principal investigator 1 Allergan, Inc. $325.00 04/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721268739
Principal investigator 1 Allergan, Inc. $100.00 04/01/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721268289
Principal investigator 1 Allergan, Inc. $975.00 04/01/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721268327
Principal investigator 1 Allergan, Inc. $19,600.00 03/24/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721266723
Principal investigator 1 Allergan, Inc. $19,600.00 03/20/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721266433
Principal investigator 1 Allergan, Inc. $400.00 03/18/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721265597
Principal investigator 1 Allergan, Inc. $75.00 03/17/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721265247
Principal investigator 1 Allergan, Inc. $27,793.20 03/17/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721265251
Principal investigator 1 Allergan, Inc. $18,603.85 03/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721263843
Principal investigator 1 Allergan, Inc. $100.00 03/09/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721262439
Principal investigator 1 Allergan, Inc. $100.00 03/09/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721262441
Principal investigator 1 Allergan, Inc. $7,000.00 03/09/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721262443
Principal investigator 1 Allergan, Inc. $150.00 03/06/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721262391
Principal investigator 1 Allergan, Inc. $200.00 03/06/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721262393
Principal investigator 1 Allergan, Inc. $325.00 03/06/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721262401
Principal investigator 1 Allergan, Inc. $975.00 03/06/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721262403
Principal investigator 1 Allergan, Inc. $100.00 03/05/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721262349
Principal investigator 1 Allergan, Inc. $325.00 03/04/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721261919
Principal investigator 1 Allergan, Inc. $325.00 03/04/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721261921
Principal investigator 1 Allergan, Inc. $400.00 03/04/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721261923
Principal investigator 1 Allergan, Inc. $650.00 03/04/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721261925
Principal investigator 1 Allergan, Inc. $100.00 02/25/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721260917
Principal investigator 1 Allergan, Inc. $8,400.00 02/25/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721260919
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $324.05 02/22/2020 Covered Recipient Physician BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD No dispute reported 06/30/2026 748802001
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $101.32 02/22/2020 Covered Recipient Physician BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD No dispute reported 06/30/2026 748802005
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $50.00 02/22/2020 Covered Recipient Physician BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD No dispute reported 06/30/2026 748802009
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $50.00 02/22/2020 Covered Recipient Physician BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD No dispute reported 06/30/2026 748802013
Principal investigator 1 Allergan, Inc. $325.00 02/21/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721258765
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $607.58 02/21/2020 Covered Recipient Physician BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD No dispute reported 06/30/2026 748801985
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $101.32 02/21/2020 Covered Recipient Physician BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD No dispute reported 06/30/2026 748801991
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $120.00 02/21/2020 Covered Recipient Physician BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD No dispute reported 06/30/2026 748801997
Principal investigator 1 Allergan, Inc. $400.00 02/20/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721258679
Principal investigator 1 Allergan, Inc. $325.00 02/19/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721258407
Principal investigator 1 Allergan, Inc. $650.00 02/18/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721258303
Principal investigator 1 Allergan, Inc. $325.00 02/18/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721258327
Principal investigator 1 Allergan, Inc. $650.00 02/18/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721258329
Principal investigator 1 Allergan, Inc. $21,886.10 02/17/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721257805
Principal investigator 1 Allergan, Inc. $36,302.35 02/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721256793
Principal investigator 1 Allergan, Inc. $325.00 02/07/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721256193
Principal investigator 1 Allergan, Inc. $19,600.00 02/05/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721256001
Principal investigator 1 Allergan, Inc. $75.00 02/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721255147
Principal investigator 1 Allergan, Inc. $75.00 02/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721255211
Principal investigator 1 Allergan, Inc. $75.00 02/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721255213
Principal investigator 1 Allergan, Inc. $75.00 02/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721255215
Principal investigator 1 Allergan, Inc. $100.00 02/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721255217
Principal investigator 1 Allergan, Inc. $100.00 02/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721255219
Principal investigator 1 Allergan, Inc. $200.00 02/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721255221
Principal investigator 1 Allergan, Inc. $200.00 02/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721255223
Principal investigator 1 Allergan, Inc. $8,400.00 02/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721255229
Principal investigator 1 Allergan, Inc. $19,600.00 02/03/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721255231
Principal investigator 1 Allergan, Inc. $700.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 721254157
Principal investigator 1 Sage Therapeutics, Inc. $1,000.00 01/23/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
217-MDD-302 No dispute reported 06/30/2026 749041395
Principal investigator 1 Sage Therapeutics, Inc. $3,000.00 01/23/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
217-MDD-302 No dispute reported 06/30/2026 749041397
Principal investigator 1 Corcept Therapeutics $5,000.00 01/22/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568733
Principal investigator 1 Corcept Therapeutics $1,000.00 01/22/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568735
Principal investigator 1 Corcept Therapeutics $800.00 01/22/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568737
Principal investigator 1 Corcept Therapeutics $5,200.00 01/22/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568739
Principal investigator 1 Corcept Therapeutics $1,500.00 01/22/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568741
Principal investigator 1 Corcept Therapeutics $3,000.00 01/22/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568745
Principal investigator 1 Corcept Therapeutics $3,000.00 01/22/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568761
Principal investigator 1 Allergan, Inc. $325.00 01/17/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721248407
Principal investigator 1 Sage Therapeutics, Inc. $6,275.00 01/16/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
217-MDD-302 No dispute reported 06/30/2026 749041209
Principal investigator 1 Sage Therapeutics, Inc. $750.00 01/16/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
217-MDD-302 No dispute reported 06/30/2026 749041211
Principal investigator 1 Sage Therapeutics, Inc. $1,000.00 01/16/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
217-MDD-302 No dispute reported 06/30/2026 749041213
Principal investigator 1 Allergan, Inc. $100.00 01/15/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721247905
Principal investigator 1 Allergan, Inc. $21,403.50 01/15/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721247913
Principal investigator 1 Allergan, Inc. $19,519.65 01/14/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721247591
Principal investigator 1 Allergan, Inc. $100.00 01/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721245947
Principal investigator 1 Allergan, Inc. $75.00 01/09/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721245881
Principal investigator 1 Allergan, Inc. $11,200.00 01/09/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721245883
Principal investigator 1 Allergan, Inc. $19,600.00 01/09/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721245885
Principal investigator 1 Allergan, Inc. $650.00 01/08/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721245683
Principal investigator 1 Allergan, Inc. $800.00 01/08/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721245685
Principal investigator 1 Allergan, Inc. $75.00 01/01/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721245209
Principal investigator 1 Allergan, Inc. $325.00 01/01/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721245211
Principal investigator 1 Allergan, Inc. $975.00 01/01/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721245215
Principal investigator 1 Allergan, Inc. $8,400.00 01/01/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721245217
Principal investigator 1 Allergan, Inc. $19,600.00 01/01/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721245219